In recent years, newer classes of medications emerged such as sodium-glucose co-transporter 2 (SGLT2) inhibitors, glucagon-like peptide-1 (GLP-1) receptor agonist, endothelin antagonists, and mineralocorticoid receptor antagonists (MRAs) are all showing great promise in the battle against DKD and its cardiovascular morbidity. This evidence concerns the gene SLC5A2 and diabetic kidney disease.